CL - Colgate-Palmolive Company
| Previous Close | 73.75 |
| Open | 73.77 |
| Bid | 69.57 x 1100 |
| Ask | 72.94 x 1800 |
| Day's Range | 72.69 - 73.88 |
| 52 Week Range | 57.41 - 75.52 |
| Volume | 2,417,398 |
| Avg. Volume | 3,188,636 |
| Market Cap | 62.414B |
| Beta (3Y Monthly) | 0.82 |
| PE Ratio (TTM) | 27.13 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.72 (2.33%) |
| Ex-Dividend Date | 2019-07-17 |
| 1y Target Est | N/A |
- Zacks•3 days ago
Colgate-Palmolive (CL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Colgate-Palmolive (CL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•3 days ago
Things You Need to Know Before FEMSA's (FMX) Q2 Earnings
FEMSA's (FMX) second-quarter 2019 results are likely to be impacted by ongoing cost headwinds, which should continue to hurt margins. However, its growth efforts might provide some respite.
- Zacks•4 days ago
Check Out Colgate's (CL) Probability to Beat in Q2 Earnings
Colgate's (CL) growth efforts indicate that it will likely retain the robust bottom-line surprise trend. However, soft margins and adverse currency may be deterrents.
- Zacks•5 days ago
Can Colgate-Palmolive (CL) Keep the Earnings Surprise Streak Alive?
Colgate-Palmolive (CL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Benzinga•10 days ago
Analyst Breaks Down Colgate's Largest Acquisition Since 1995
Colgate-Palmolive Company (NYSE: CL ) acquired Laboratories Filorga in a move which will support growth amid global challenges, according to Bank of America. The Analyst Bank of America's Olivia Tong maintains ...
- Benzinga•10 days ago
Johnson & Johnson Falls On Report Of Justice Department Probe
The investigation is focused on whether J&J deceived the public about the risk of cancer linked to its talcum powder, sources told Bloomberg. A grand jury in Washington is examining documents that may shed light as to what company executives knew about the potential dangers of the talc powder, the report said. The Justice Department didn't respond to Bloomberg's request for comment.
- Zacks•10 days ago
Colgate (CL) to Expand Skin Care Range With Filorga Buyout
Colgate (CL) to expand the personal care portfolio with the acquisition of skin care business of France-based Filorga.
- TheStreet.com•10 days ago
Colgate-Palmolive to Buy Filorga Skin Care Business for $1.69 Billion
Colgate-Palmolive is buying the skin care business of the French company Laboratoires Filorga Cosmetiques for about $1.69 billion.
- Motley Fool•10 days ago
After Hours: Illumina Issues a Warning, Colgate-Palmolive Makes an Acquisition
The DNA sequencing specialist indicates its Q2 revenue won't be as high as previously expected, while the consumer goods giant pushes deeper into the cosmetics segment.
- Financial Times•10 days ago
Colgate-Palmolive to buy French skincare business for €1.5bn
Colgate-Palmolive has reached an agreement to buy the Filorga Cosmétiques skincare business for €1.5bn, a sign the US consumer goods group is turning to deals to diversify its interests beyond toothpaste and soap. Filorga, based in Paris, is an anti-ageing skin care brand focused primarily on facial care. The purchase is notable for Colgate, which despite its size had been reticent over mergers and acquisitions under longtime chief executive Ian Cook.
- Reuters•11 days ago
UPDATE 1-Colgate to buy skin care business of France's Filorga for $1.69 bln
Colgate-Palmolive Co said on Thursday it would buy the skin care unit of France's Laboratoires Filorga Cosmétiques for 1.50 billion euros ($1.69 billion), as the consumer goods company bolsters its personal care business. Filorga's anti-aging skin care products are sold in over 60 countries, with its largest markets being France, Italy, Spain and Greater China. "This acquisition also provides Colgate entry into the fast-growing and sizeable travel retail channel, particularly in Asia," Chief Executive Officer Noel Wallace said.
- Zacks•12 days ago
Colgate's (CL) Growth Efforts Well on Track Amid Soft Margins
Colgate's (CL) strong surprise trend, higher pricing, strong innovation and expansion efforts bode well. However, high input costs and currency headwinds concerns.
- American City Business Journals•13 days ago
Atlanta Braves director, Kennesaw State VP among Leadership Cobb Class of 2020 (Slideshow)
The 2019-2020 class of Leadership Cobb is set. The Cobb Chamber on Monday announced the 50 members (26 men, 24 women) of this year's leadership development program that's focused on personal and professional growth.
- Markit•13 days ago
See what the IHS Markit Score report has to say about Colgate-Palmolive Co.
Colgate-Palmolive Co NYSE:CLView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CL. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $6.63 billion over the last one-month into ETFs that hold CL are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. CL credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•14 days ago
Soap & Cleaning Materials Industry Outlook Upbeat on New Products
Soap & Cleaning Materials Industry Outlook Upbeat on New Products
- Market Realist•19 days ago
Can Personal Care Players Keep Producing Double-Digit Returns?
Shares of most US household and personal care manufacturers generated double-digit returns in the first half. What does the future hold?
- MarketWatch•20 days ago
Cannabis sector could grow to $200 billion in a decade, say Stifel analysts
The cannabis sector offers a $200 billion global opportunity in the next decade, up from the roughly $8 billion that was generated in 2018 in federal legal markets and U.S. state licensed sales, Stifel analysts wrote Tuesday in a new report. Market leader Canopy Growth Corp. disappointed investors with weaker-than-expected earnings last week and mixed outlook, as elevated costs during the current investment phase lowered gross margin forecasts, said the report. "While the near-term execution at Canopy is underwhelming likely driving a portion of the elevated expenses, we remain confident that Canopy is best positioned to tackle all avenues for growth in the $200 billion global category," the analysts led by Andrew Carter wrote in the report. In the same vein, Canada currently represents the most significant near-term opportunity, as the only G-7 country to have fully legalized cannabis last October. Stifel is expecting Canada to achieve C$10 billion in annual sales by 2023. "The market is quickly taking shape with the latest update from Stats Canada suggesting a C$ 900 million annualized market in April with sales in the month up 23% sequentially likely driven by the cannabis enthusiast holiday 4/20 and initial store openings in Ontario," said the report. But Canada sales will be eclipsed by the U.S. which offers a $100 billion opportunity over the next decade, the analysts wrote. That opportunity will change if federal rules are relaxed, which Stifel is expecting is at best a 2021 possibility. "While there has been a flurry of legislation in Congress with a number of items achieving success in the House of Representatives, we believe the political calculus of Senate majority leader Senator Mitch McConnell favors keeping any cannabis legislation from reaching the Senate floor for a vote," they wrote. "While cannabis enjoys bipartisan approval, we contend the issue of change at the federal level is not salient with American voters." The report noted the three companies that are expected to benefit from legalization in Illinois, which last week became the first state to legalize through the state legislature and not through the ballot box. Cresco Labs Inc. , Green Thumb Industries Inc. and PharmaCann, the state's three medical operators, are expected to benefit. The ETFMG Alternative Harvest ETF has gained 29% in 2019 to date, while the S&P 500 has gained 18%.
- Investopedia•23 days ago
The Top Nike Shareholders (NKE)
Learn about the history of Nike Inc. and the top shareholders who continue to benefit from the company's explosive success.
- TheStreet.com•23 days ago
These 3 Dividend Aristocrats Have Consumable Products as Part of Their Offerings
When we talk Dividend Aristocrats and Dividend Kings, it should come as little surprise the Kings and their more than 50 years of increasing dividends earns the same as a lot in the Dividend Aristocrats, given they easily satisfy the criteria that is increasing their dividends for at least 25 years. This led me to suggest investors through the Kings for companies that have inelastic and defensible business models. Now let's do the same for the Dividend Aristocrats.
- Simply Wall St.•25 days ago
Have Insiders Been Selling Colgate-Palmolive Company (NYSE:CL) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Market Realist•28 days ago
Church & Dwight Continues to Outperform with Its Earnings Growth
Church & Dwight’s (CHD) earnings have grown at a strong double-digit rate in the past several quarters and have outpaced those of its rivals. The company has surpassed Wall Street’s expectations in five out of the past six quarters.
- Market Realist•last month
Why Wall Street Suggests ‘Hold’ for Colgate-Palmolive Stock
Colgate-Palmolive's (CL) improved organic sales and better-than-expected earnings have boosted its stock in the past two quarters.
- Market Realist•last month
This Could Continue to Hurt Colgate-Palmolive’s EPS
While Colgate-Palmolive (CL) has beaten Wall Street’s EPS expectations in the past two quarters, its adjusted EPS have fallen in the past three quarters.
- Market Realist•last month
Colgate-Palmolive’s Revenue Unlikely to Impress
Whereas Colgate-Palmolive’s (CL) top line beat analysts' estimate in the first quarter, it has missed their estimates in four of the past five quarters.
- Market Realist•last month
Colgate-Palmolive Stock: Is a Pullback around the Corner?
Colgate-Palmolive (CL) stock has gained substantially this year, outperforming broader markets. The stock has risen 23.3%, while the S&P 500 has risen 15.3%. Let's look at what's boosted the stock.
